Author

Lucia Rojikova

Cancer Research Institute of the Slovak Academy of Sciences

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Andrea ČumováiD· 1 shared Andrea ŠoltýsováiD· 1 shared Andrej FicekiD· 1 shared Boris TichýiD· 1 shared Božena SmolkováiD· 1 shared Eva SedláčkováiD· 1 shared Florence BusatoiD· 1 shared Geir Frode Øy· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea ČumováORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Development of Paclitaxel Resistance in Triple-Negative Breast Cancer Is Associated with Extensive DNA Methylation Changes That Are Partially Reversed by Decitabine

Lenka Trnkova, Monika Buríková, Andrea Šoltýsová, Andrej Ficek, Jana Plavá, Andrea Čumová, Lucia Rojikova, Kristína Jakič, Eva Sedláčková, Boris Tichý, Vojtěch Bystrý, Florence Busato, Yimin Shen, Miroslava Matúšková, Lucia Kučerová, , Božena Smolková

This study shows that paclitaxel resistance in triple-negative breast cancer is linked to DNA methylation changes, which can be partially reversed by decitabine to enhance chemosensitivity.

Drug Resistance Updates · Jan 2, 2026Peer-reviewedCancer Biology